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Abstract
Background: The HLA DRB1*08 allele associated with primary biliary cholangitis (PBC) among Caucasians is of low
frequency in the Sardinian population.
Objective: The aim of our study was to type a cohort of PBC patients from the island of Sardinia for HLA class II antigens.
Methods: Twenty Sardinian patients affected by PBC, 14 with autoimmune hepatitis (AIH) and 89 healthy controls (HCs) were
typed for HLA class II alleles by dot-blot analysis.
Results: The PBC-associated HLA DRB1*08 allele was detected in none of the studied individuals. The DRB1*0301–
DQB1*0201 was the prevalent HLA haplotype, detected in 19 (47.5%) out of 40 PBC haplotypes (OR¼ 3.0; 95% CI
1.5–6.2) and in 11 (39.3%) out of 28 AIH haplotypes (OR¼ 2.2; 95% CI 0.94–5.0), but in only 41 (23%) out of 178 HC
haplotypes. Moreover, PBC patients showed an increased frequency of homozygosity for the DQB1*0201 allele (35%
compared with 6.7% of the HCs; OR¼ 7.5; 95% CI 2.2–25.7). The frequency of the DRB1*11 allele in the PBC group was
about half of that seen in the Sardinian HCs (7.5% vs 15.7%) (p¼ ns).
Conclusions: Our study confirmed the low frequency of the HLA DRB1*08 allele among Sardinians, either in the general
population or PBC patients. The high prevalence of the HLA DRB1*0301–DQB1*0201 haplotype is a distinctive genetic feature
of PBC among Sardinians. Our study strengthens the hypothesis that still unknown genetic, epigenetic, and environmental
factors must be involved in the pathogenesis of different HLA-associated liver diseases, and it represents a pathfinder that
warrants exploration in a future extensive study.
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Introduction
Primary biliary cholangitis1 is the recently proposed
name for primary biliary cirrhosis (PBC), a chronic,
non-suppurative cholangitis of still unknown etiology,
characterized by the progressive destruction of the
small intrahepatic bile ducts, which might eventually
lead to end-stage liver failure.2 PBC is likely a multifac-
torial disease resulting from the interaction of genetic
and environmental factors, including a possible infec-
tious agent3 and epigenetic mechanisms,4 as suggested
by its predominance in females, its pattern of occur-
rence in twins, its prevalence in speciﬁc geographical
areas, and its frequent clustering with autoimmune
diseases within the same family.1–6 PBC presents with
clinical and histological features highly suggestive of an
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immune-mediated pathogenesis, such as T-lymphocyte
and plasma cell inﬁltration of biliary ducts, highly
speciﬁc circulating autoantibodies and association
with autoimmune diseases.2 Serum antimitochondrial
antibodies (AMA) are the hallmark of PBC,7 and one
of the major autoantigens is the E2-subunit of the pyru-
vate dehydrogenase complex (PDC-E2).
Unlike in autoimmune hepatitis (AIH) and other
immune-mediated diseases, the human leukocyte anti-
gen (HLA) DRB1*08 allele has been recognized as the
major HLA antigen predisposing to PBC in Caucasian
and Asian populations.8–10 However, in sporadic cases
with PBC11 and in the Danish population,12 HLA-
DRB1*0301–DQB1*0201 is the prevalent haplotype
associated with PBC. Studies on the distribution of
HLA class II haplotypes have revealed that
Sardinians have a highly homogeneous genetic back-
ground that is distinct from that of other Caucasian
populations.13 In particular, the HLA DRB1*08 allele
has an extremely low frequency in Sardinia,13 but no
study has investigated the frequency of this allele in
Sardinian PBC patients. The aim of this study was to
evaluate the prevalence of HLA class II genes in a




Twenty patients (mean age, 57.7 15.3 years, female/
male (F/M) ratio of 18/2) aﬀected by PBC were typed
for HLA class II genes along with 14 patients (mean
age, 29.8 19.2 years with an F/M ratio of 5/9) aﬀected
by AIH. As an independent Sardinian cohort, we ana-
lyzed 89 ethnically matched healthy controls (HCs)
with no family history of autoimmune disorders from
the Blood Transfusion Service of the Azienda
Ospedaliera Brotzu, Cagliari, Italy. Moreover, data
previously published on HLA class II haplotypes in a
large cohort of 631 randomly selected newborns were
also included as controls for the Sardinian general
population.13 The diagnosis of PBC was in line with
the guidelines published by the American Association
for the Study of Liver Diseases.14 All our patients had
biochemical evidence of cholestasis with elevation of
alkaline phosphatase activity, and all were positive for
AMA reacting with AMA-E2. None of the 20 PBC
patients showed evidence of overlapping AIH.14
According to the AIH classiﬁcation,15 among the 14
AIH patients analyzed, eight were Type 1 AIH and
six Type 2 AIH. All the patients and controls enrolled
in this study were of Sardinian descent. All provided
informed consent.
HLA class II genes
DNA was extracted using the method previously
reported.13 Ampliﬁcation of the polymorphic second
exon of 23 DRB1, DQB1 genes and dot-blot analysis
of ampliﬁed DNA with sequence-speciﬁc oligonucleo-
tide probes were performed using the previously
described oligonucleotide probes and procedures.13
Statistical evaluation
The association with distinct HLA variants was eval-
uated between groups with 2 test. Fisher’s exact test
was used when appropriate. Odds ratios (ORs)
were calculated considering as controls the HCs and
the previously published Sardinian newborns.13
Ninety-ﬁve percent conﬁdence intervals (95% CI) on
ORs were calculated according to the Woolf
method.16 All p values are two sided, and p
values 0.05 are considered to be statistically signiﬁ-
cant. Statistical analysis was carried out using the
statistical software Stata 11.0 (StataCorp LP,
College Station, TX, USA).
Results
Table 1 shows the DRB1, DQB1 genotypes of the 20
PBC patients, 14 AIH patients and 89 HCs. The
most frequent genotype detected in Sardinian PBC
patients was the DRB1*0301–DQB1*0201/
DRB1*0301–DQB1*0201 homozygosity (20% com-
pared with 5.6% in HCs). It is interesting that the
second most frequent genotype detected in PBC
patients was DRB1*0301–DQB1*0201/DRB1*0701–
DQB1*0201 (15% compared with 1.1% in HCs),
which share the same homozygosity at the DQB1
locus. Therefore, in Sardinia, PBC patients showed an
increased frequency of homozygosity for the
DQB1*0201 allele (35% compared with 6.7% of the
HCs; OR¼ 7.5; 95% CI 2.2–25.7).
In Table 2 the frequencies of the six major DRB1,
DQB1 haplotypes detected in our PBC and AIH
patients are shown in comparison to HCs and those
previously published in Sardinian newborns, respect-
ively. The DRB1*0301–DQB1*0201 was the prevalent
HLA haplotype, detected in 19 (47.5%) out of 40 PBC
haplotypes (OR¼ 3.0; 95% CI 1.5–6.2 and 3.2, 95% CI
1.7–6.1, respectively) and in 11 (39.3%) out of 28 AIH
haplotypes (OR¼ 2.2; 95% CI 0.94–5.0 and 2.3, 95%
CI 1.1–5.0, respectively), but only in 41 (23.0%) out of
178 HC haplotypes and in 277 (21.9%) out of 1262
Sardinian newborns. No diﬀerence in the frequency of
this HLA haplotype was found between PBC and AIH
groups (Table 2, 47.5% vs 39.3%; p¼ ns).
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Table 3 shows the distribution of PBC-associated
HLA DRB1 alleles in Italian8 vs Sardinian individuals,
both in the general population and those with PBC.
The frequency of the HLA DRB1*0301 allele was
two-fold higher in Sardinian PBC patients compared
both to the Sardinian HCs and Sardinian newborns,
while among continental Italians no diﬀerences in
HLA DRB1*0301 frequency were observed among
groups.8 As regards to HLA DRB1*08, our results con-
ﬁrmed the very low frequency of this allele among
Sardinians, either in the general population or in PBC
patients. Conversely, the frequency of this allele was
about three-fold higher in Italian PBC patients com-
pared to the Italian general population.8
The HLA DRB1*08 allele was not detected in any of
the participants tested (Tables 1–3). Two HLA class II
alleles (Table 3), namely HLA DRB1*11 and DRB1*13,
have been recently described as conferring protection
against PBC among Caucasians.8 While in our series
the DRB1*13 allele showed similar frequency between
groups, the DRB1*11 allele frequency in the PBC group
was about half of that seen in the Sardinian HCs or
newborns (7.5% vs 15.7% and 13.5%, respectively), a
ﬁnding that lacked statistical signiﬁcance (p¼ ns).
Discussion
The Sardinian population has a high degree of genetic
homogeneity.13 HLA class II genes have a unique and
very homogeneous distribution in all the districts of the
island.13 In spite of its geographical location,
when compared to other Caucasians, Sardinians show
a very high frequency of the HLA DRB1*0301–
DQB1*0201 haplotype, which is responsible for the
high genetic susceptibility to clinically overt auto-
immune diseases, including type 1 diabetes,
Hashimoto’s thyroiditis, celiac disease and multiple
sclerosis.17–19 In particular, multiple sclerosis has been
associated with the HLA DRB1*0301–DQB1*0201
haplotype only in Sardinia but not in other Caucasian
populations where the association involves a diﬀerent
HLA DRB1 allele.20 Similarly, we found that Sardinian
PBC patients lack expression of HLA DRB1*08, which
is the major HLA allele conferring predisposition to
PBC in other Caucasian and Asian populations, while
carrying the same HLA haplotype that predisposes to
other, both hepatic and extra-hepatic, immune-
mediated diseases.15 Thus, along with type 1 diabetes,
Table 2. Frequency of the six major DRB1, DQB1 haplotypes in Sardinian PBC (a) and AIH (b) patients in comparison to healthy controls













(n¼ 1262) (a) vs (c) (a) vs (d) (b) vs (c) (b) vs (d)
0301 0201 19 (47.5%) 11 (39.3%) 41 (23.0%) 277 (21.9%) p< 0.05 p< 0.001 p¼ ns p< 0.05
0402–5 0302 2 (5.0%) 4 (14.3%) 3 (1.7%) 94 (7.5%) p¼ ns p¼ ns p¼ ns p¼ ns
0701 0201 4 (10.0%) 1 (3.6%) 6 (3.4%) 69 (5.5%) p¼ ns p¼ ns p¼ ns p¼ ns
1101–4 0301 3 (7.5%) 2 (7.1%) 28 (15.7%) 171 (13.5%) p¼ ns p¼ ns p¼ ns p¼ ns
1301–3 060 1 (2.5%) 1 (3.6%) 2 (1.1%) 35 (2.8%) p¼ ns p¼ ns p¼ ns p¼ ns
1601 0502 6 (15.0%) 3 (10.7%) 37 (20.8%) 241 (19.0%) p¼ ns p¼ ns p¼ ns p¼ ns
PBC: primary biliary cholangitis; AIH: autoimmune hepatitis.
Table 1. Distribution of DRB1, DQB1 genotypes in patients with
PBC or AIH and HCs.
No. DRB1–DQB1 genotype PBC (20) AIH (14) HCs (89)
1 0301–0201/0301–0201 4 (20%) 1 (7%) 5 (5.6%)
2 0301–0201/0701–0201 3 (15%) – 1 (1.1%)
3 0301–0201/0101–0501 2 (10%) – 4 (4.5%)
4 0301–0201/1601–0502 2 (10%) 2 (14.2%) 5 (5.6%)
5 0301–0201/110–0301 2 (10%) 2 (14.2%) 10 (11%)
6 0301–0201/1401–0503 1 (5%) 1 (7%) 2 (2.2%)
7 0301–0201/040–0302 1 (5%) – 1 (1.1%)
8 0301–0201/1001–0501 – 2 (14.2%) 2 (2.2%)
9 0301–0201/130–060 – 1 (7%) –
10 0301–0201/040–0302 – 1 (7%) 1 (1.1%)
11 1601–0502/1601–0502 1 (5%) – 5 (5.6%)
12 1601–0502/040–0302 1 (5%) – –
13 1601–0502/110–0301 1 (5%) – –
14 1601–0502/0101–0501 1 (5%) – –
15 0701-0201/130-060 1 (5%) – –
16 0701–0201/1601–0502 – 1 (7%) –
17 040–0302/040–0302 – 1 (7%) –
18 040–0302/0101–0501 – 2 (14.2%) –
PBC: primary biliary cholangitis; AIH: autoimmune hepatitis; HCs: healthy
controls;
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Hashimoto’s thyroiditis, celiac disease and multiple
sclerosis, at least in the Sardinian population,
DRB1*0301–DQB1*0201 appears to be associated
also with PBC and AIH.
Moreover, Sardinian PBC patients showed an
increased homozygosity for the DQB1*0201 allele. In
celiac disease, the HLA DQB1*0201 homozygosity
inﬂuences the severity of the intestinal mucosa lesions
in a dose-dependent manner.18 Future studies could
therefore investigate whether a dose-dependent eﬀect
of HLA DQB1*0201 homozygosity may aﬀect the nat-
ural course and outcome of PBC in Sardinia. In paral-
lel, two HLA alleles (DRB1*11 and DRB1*13) recently
reported to confer protection against PBC in
Caucasians8 were not signiﬁcantly diﬀerent between
PBC and controls in our study, even if the lack of stat-
istical diﬀerence was likely due to the low power of the
study, at least for the DRB1*11 allele.
Considering the high genetic risk of autoimmune dis-
eases in Sardinia, it was important to include in our
study an independent cohort of Sardinian adult healthy
controls with no family history for autoimmune dis-
eases, as some of the newborns considered as
Sardinian ‘‘general population’’ are expected to develop
autoimmune diseases later in life. The high frequency of
the DRB1*0301–DQB1*0201 genes in the Sardinian
population has been explained by the selective advan-
tage of an increased immune protection toward epi-
demic infectious diseases, like malaria and plague,
which have caused substantial mortality in the history
of the island.21,22 Therefore, the selection of speciﬁc
genetic traits among the surviving Sardinians could be
responsible, at least in part, for the high frequency of
autoimmune diseases observed on the island today.21,22
The reason why the DRB1*08 allele is underrepre-
sented in Sardinia, and especially in Sardinian PBC
patients, is not clear. Besides the role played by selective
forces, the peculiar distribution of HLA genes found in
all the various regions of the island is suggestive of an
ancestral origin likely due to a founder eﬀect on a popu-
lation that has remained genetically unaﬀected by exter-
nal immigration.13,22 Moreover, recent genome-wide
association studies (GWAS) showed that genetic predis-
position to PBCmainly lies within theHLA region;23 the
non-HLA risk loci so far identiﬁed are similar in hepatic
and non-hepatic immune-mediated diseases,24 indicat-
ing that each disease phenotype must be attributable
to the involvement of other factors.
These ﬁndings strongly suggest that multiple factors
play a role in the pathogenesis of autoimmune diseases,
which likely arise from a complex interaction between
genes and acquired factors. The results of our study pro-
vide further evidence that theSardinianpopulation is char-
acterized by a diﬀerent genetic background compared to
other populations. Several immune-mediated disorders
may be linked to peculiar HLA haplotypes, in support of
the concept that HLA associations with diseases might
vary depending on the geographical areas.6,14 Moreover,
besidesHLAassociations, other unknown genetic, epigen-
etic, and environmental factors, including an infectious
agent/s, might be implicated in the pathogenesis and clin-
ical evolution of PBC or other autoimmune diseases.
Conclusions, strength and weakness
of the study
To the best of our knowledge, this is the ﬁrst study on
HLA class II alleles in a cohort of Sardinian PBC
patients, where for the ﬁrst time signiﬁcant diﬀerences
emerged compared with PBC patients in continental
Italian or other Caucasian populations. These results
may highlight that Sardinians diﬀer from other
Caucasian populations not only in regards to the gen-
etic background of the general population but also for
speciﬁc genetic risks associated with immune-mediated
disorders. This study represents a pathﬁnder on this
topic, which warrants exploration in future, more
extensive, studies.
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Table 3. Frequency of PBC-related HLA DRB1 alleles in the general population and in PBC patients—both Italian (8) and Sardinian.
n. alleles DRB1*03 DRB1*08 DRB1*11 DRB1*13
Italian population 3984 7.8% 2.3% 30% 11.2%
Italian PBC 1328 10.9% 7.2% 13.6% 8.6%
Sardinian newborns 1262 21.9% 1% 13.5% 2.8%
Sardinian healthy controls 178 23.0% 0% 15.7.% 1.1%
Sardinian PBC 40 47.5% 0% 7.5% 2.5%
PBC: primary biliary cholangitis; HLA: human leukocyte antigen.
530 United European Gastroenterology Journal 5(4)
References
1. Shimoda S and Tanaka A. It is time to change PBC: New
nomenclature from ‘‘cirrhosis’’ to ‘‘cholangitis’’, and
upcoming treatment based on unveiling pathology.
Hepatol Res 2016; 46: 407–415.
2. Purohit T and Cappell MS. Primary biliary cirrhosis:
Pathophysiology, clinical presentation and therapy.
World J Hepatol 2015; 7: 926–941.
3. Sharon D and Mason AL. Role of novel retroviruses in
chronic liver disease: Assessing the link of human betar-
etrovirus with primary biliary cirrhosis. Curr Infect Dis
Rep 2015; 17: 460.
4. Xie YQ, Ma HD and Lian ZX. Epigenetics and primary
biliary cirrhosis: A comprehensive review and implica-
tions for autoimmunity. Clin Rev Allergy Immunol 2016;
50: 390–403.
5. Selmi C, Mayo MJ, Bach N, et al. Primary biliary cirrho-
sis in monozygotic and dizygotic twins: Genetics, epigen-
etics, and environment. Gastroenterology 2004; 127:
485–492.
6. Tanaka A, Borchers AT, Ishibashi H, et al. Genetic and
familial considerations of primary biliary cirrhosis. Am
J Gastroenterol 2001; 96: 8–15.
7. Leung PS, Choi J, Yang G, et al. A contemporary per-
spective on the molecular characteristics of mitochondrial
autoantigens and diagnosis in primary biliary cholangitis.
Expert Rev Mol Diagn 2016; 16: 697–705.
8. Invernizzi P, Selmi C, Poli F, et al. Human leukocyte
antigen polymorphisms in Italian primary biliary cirrho-
sis: A multicenter study of 664 patients and 1992 healthy
controls. Hepatology 2008; 48: 1906–1912.
9. Donaldson PT, Baragiotta A, Heneghan MA, et al. HLA
class II alleles, genotypes, haplotypes, and amino acids in
primary biliary cirrhosis: A large-scale study. Hepatology
2006; 44: 667–674.
10. Umemura T, Joshita S, Ichijo T, et al. Human leukocyte
antigen class II molecules confer both susceptibility and
progression in Japanese patients with primary biliary cir-
rhosis. Hepatology 2012; 55: 506–511.
11. Manns MP, Bremm A, Schneider PM, et al. HLA DRw8
and complement C4 deficiency as risk factors in primary
biliary cirrhosis. Gastroenterology 1991; 101: 1367–1373.
12. Morling N, Dalhoff K, Fugger L, et al. DNA polymorph-
ism of HLA class II genes in primary biliary cirrhosis.
Immunogenetics 1992; 35: 112–116.
13. Lampis R, Morelli L, De Virgiliis S, et al. The distribu-
tion of HLA class II haplotypes reveals that the Sardinian
population is genetically differentiated from the other
Caucasian populations. Tissue Antigens 2000; 56:
515–521.
14. Lindor KD, Gershwin ME, Poupon R, et al. Primary
biliary cirrhosis. Hepatology 2009; 50: 291–308.
15. Manns MP, Lohse AW and Vergani D. Autoimmune
hepatitis—Update 2015. J Hepatol 2015; 62(1 Suppl):
S100–S111.
16. Woolf B. On estimating the relation between blood group
and disease. Ann Hum Gen 1955; 19: 251–253.
17. Motzo C, Contu D, Cordell HJ, et al. Heterogeneity in
the magnitude of the insulin gene effect on HLA risk in
type 1 diabetes. Diabetes 2004; 53: 3286–3291.
18. Jores RD, Frau F, Cucca F, et al. HLA-DQB1*0201
homozygosis predisposes to severe intestinal damage in
celiac disease. Scand J Gastroenterol 2007; 42: 48–53.
19. Sotgiu S, Pugliatti M, Sanna A, et al. Multiple sclerosis
complexity in selected populations: The challenge of
Sardinia, insular Italy. Eur J Neurol 2002; 9: 329–341.
20. Marrosu MG, Murru MR, Costa G, et al. Multiple scler-
osis in Sardinia is associated and in linkage-disequili-
brium with HLA-DR3 and-DR4 alleles. Am J Hum Gen
1997; 61: 454–457.
21. Sotgiu S, Pugliatti M, Sotgiu A, et al. Does the ‘‘hygiene
hypothesis’’ provide an explanation for the high preva-
lence of multiple sclerosis in Sardinia? Autoimmunity
2003; 36: 257–260.
22. Sanna MV, Clemente M, Bartfai T, et al. Potential role
for the plague as a selective force in Sardinia. Igiene
Moderna 2007; 127: 15–42.
23. Mells GF, Kaser A and Karlsen TH. Novel insights into
autoimmune liver diseases provided by genome-wide
association studies. J Autoimmun 2013; 46: 41–54.
24. Cordell HJ, Han Y, Mells GF, et al. International
genome-wide meta-analysis identifies new primary biliary
cirrhosis risk loci and targetable pathogenic pathways.
Nat Commun 2015; 6: 8019.
Clemente et al. 531
